Compare ATS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | VRDN |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2023 | N/A |
| Metric | ATS | VRDN |
|---|---|---|
| Price | $26.62 | $33.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $39.73 |
| AVG Volume (30 Days) | 100.1K | ★ 1.6M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,930,283,080.00 | $70,789,000.00 |
| Revenue This Year | $17.12 | $26,477.48 |
| Revenue Next Year | $5.12 | $6.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23340.07 |
| 52 Week Low | $20.90 | $9.90 |
| 52 Week High | $32.73 | $33.34 |
| Indicator | ATS | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 67.37 |
| Support Level | $26.89 | $32.29 |
| Resistance Level | $28.11 | $33.29 |
| Average True Range (ATR) | 0.68 | 1.19 |
| MACD | 0.22 | -0.15 |
| Stochastic Oscillator | 60.91 | 77.75 |
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).